Evaluation of the effects of childhood obesity and metabolic syndrome on subclinic inflammatory markers and monocyte/HDL-K ratio

Objective: In this study, we aimed to enable the use of inflammation markers, since childhood obesity and metabolic syndrome are inflammatory diseases in the diagnosis and follow-up. It is to establish parameters that can pre-evaluate the complications caused by obesity and metabolic syndrome and plan treatment and follow-up to prevent these complications from occurring. Method: Individuals consisting of 86 children and adolescents aged 10-18 years who applied to the Tokat Gaziosmanpaşa University Hospital Pediatric Health and Diseases outpatient clinic were included. The study was done retrospectively. BMI values were calculated using height and weight measurements. It was calculated according to the formula BMI=Weight (kg) / Height (m2). According to the BMI percentile curve, those who were at the 95th percentile and above were considered obese. Metabolic syndrome diagnostic criteria used in our study; obesity (BMI 95th percentile and above), glucose metabolism disorder (Insulin resistance or diabetes mellitus), hypertension (systolic and/or diastolic blood pressure, 95th percentile and above) and dyslipidemia (TG, TK and/or LDL- K level is 95th percentile and above and/or HDL-K is 5th percentile and below). If at least three of these four criteria are present, a diagnosis of metabolic syndrome was made. NLR (Neutrophil/Lymphocyte ratio), TLR (Platelet/Lymphocyte ratio), MPV, RDW, WBC and CRP values were taken as subclinical inflammation indicators from the previous hemogram values obtained from the patient and control groups. Findings: According to the results we obtained in our study, the BMI of the control group was found to be 24,75±2,12, 32,57±4,37 for the metabolic syndrome group and 31,90±5,20 for the obese group. When the BMI percentile values of the patients were compared, according to the results we obtained, the BMI percentile for the control group was 88,05±9,75, the BMI percentile for the metabolic syndrome group was 96,63±1,83 and the BMI percentile for the obese group was 99,58±0,65. When the groups were compared, it was seen that there was a significant difference in HDL-C, Insulin, HOMA-IR, Systolic and Diastolic blood pressures in the metabolic syndrome group compared to the obese group and the control group. In our study, WBC, RDW, MPV, TLR and NLR values, which were evaluated as subclinical inflammation markers, were compared between the control group, the obese group and the group with metabolic syndrome. As a result of the comparison, no statistically significant difference was found between the groups. A statistically significant difference was found when the acute phase reactant CRP values of the patients were compared between control, obese and metabolic syndrome patients. It was found to be 2,64±3,66 in the control group, 4,76±3,29 in the obese patient group, and 5,30±4,41 in the metabolic syndrome patient group. (p:0.031). Conclusion: CRP value was higher in the metabolic patient group than in the control group. We found a positive correlation between CRP and Monocyte/HDL-Cholesterol. This made us think that CRP value can be used as a subclinical inflammation marker in patients with metabolic syndrome. Keywords: C-Reactive Protein, Metabolic Syndrome, Obesity, Subclinical Inflammation Markers